Oncoinvent to present at the 30th Annual Congress of the European Association of Nuclear Medicine – EANM

Researchers Sara Westrøm and Elisa Napoli will each be presenting findings of their research during the morning session on Sunday the 22nd of October

Organiser: EANM
Venue:

Austria Center Vienna, Bruno Kreisky Platz 1,Vienna, 1210 Austria


Date: 21 October 2017
Program:

Anders Månsson

Chief Executive Officer

mansson@oncoinvent.com

Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.

Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.